Company intelligence / Profile preview

Cypralis

Cambridge, England, United Kingdomcypralis.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Cypralis has developed novel small molecule cyclophilin inhibitors. Its lead candidate, CC‑4066, has completed Phase 1 clinical trials for the prevention and treatment of acute kidney injury associated with major surgery. The company is also advancing preclinical programs targeting neurodegeneration and other indications by developing brain‑penetrant cyclophilin D inhibitors.

Therapeutic areas: GastroenterologyNeurologyNephrology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

3 assets

CC-1233

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Farsight Medical Technology (Shanghai) CO., Ltd. – for preclinical and clinical development in China

Beyond the preview

Go deeper on Cypralis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cypralis.

Explore the full profile